Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes.

Schwake C, Baldwin MR, Bachovchin W, Hegde S, Schiemer J, Okure C, Levin AE, Vannier E, Hanada T, Chishti AH.

Biochem Biophys Res Commun. 2019 Sep 10;517(1):125-131. doi: 10.1016/j.bbrc.2019.07.031. Epub 2019 Jul 13.

PMID:
31311649
2.

Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death.

Larkin B, Ilyukha V, Sorokin M, Buzdin A, Vannier E, Poltorak A.

J Immunol. 2017 Jul 15;199(2):397-402. doi: 10.4049/jimmunol.1601999. Epub 2017 Jun 14.

3.

A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse.

Lemieux JE, Tran AD, Freimark L, Schaffner SF, Goethert H, Andersen KG, Bazner S, Li A, McGrath G, Sloan L, Vannier E, Milner D, Pritt B, Rosenberg E, Telford S 3rd, Bailey JA, Sabeti PC.

Nat Microbiol. 2016 Jun 13;1(7):16079. doi: 10.1038/nmicrobiol.2016.79.

4.

Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6.

Belizário JE, Fontes-Oliveira CC, Borges JP, Kashiabara JA, Vannier E.

Springerplus. 2016 May 13;5:619. doi: 10.1186/s40064-016-2197-2. eCollection 2016. Review.

5.

Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.

Sanchez E, Vannier E, Wormser GP, Hu LT.

JAMA. 2016 Apr 26;315(16):1767-77. doi: 10.1001/jama.2016.2884. Review.

PMID:
27115378
6.

Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences.

Diuk-Wasser MA, Vannier E, Krause PJ.

Trends Parasitol. 2016 Jan;32(1):30-42. doi: 10.1016/j.pt.2015.09.008. Epub 2015 Nov 21. Review.

7.

Babesiosis.

Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ.

Infect Dis Clin North Am. 2015 Jun;29(2):357-70. doi: 10.1016/j.idc.2015.02.008. Review.

8.

Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.

Bancovik J, Moreira DF, Carrasco D, Yao J, Porter D, Moura R, Camargo A, Fontes-Oliveira CC, Malpartida MG, Carambula S, Vannier E, Strauss BE, Wakamatsu A, Alves VA, Logullo AF, Soares FA, Polyak K, Belizário JE.

BMC Cancer. 2015 Feb 19;15:70. doi: 10.1186/s12885-015-1022-6.

9.

Borrelia burgdorferi promotes the establishment of Babesia microti in the northeastern United States.

Dunn JM, Krause PJ, Davis S, Vannier EG, Fitzpatrick MC, Rollend L, Belperron AA, States SL, Stacey A, Bockenstedt LK, Fish D, Diuk-Wasser MA.

PLoS One. 2014 Dec 29;9(12):e115494. doi: 10.1371/journal.pone.0115494. eCollection 2014.

10.

Babesiosis in China, an emerging threat.

Vannier E, Krause PJ.

Lancet Infect Dis. 2015 Feb;15(2):137-9. doi: 10.1016/S1473-3099(14)71062-X. Epub 2014 Dec 22. No abstract available.

PMID:
25539585
11.

Human babesiosis.

Vannier E, Krause PJ.

N Engl J Med. 2012 Jun 21;366(25):2397-407. doi: 10.1056/NEJMra1202018. No abstract available.

PMID:
22716978
12.

Effects of resistance exercise combined with essential amino acid supplementation and energy deficit on markers of skeletal muscle atrophy and regeneration during bed rest and active recovery.

Brooks NE, Cadena SM, Vannier E, Cloutier G, Carambula S, Myburgh KH, Roubenoff R, Castaneda-Sceppa C.

Muscle Nerve. 2010 Dec;42(6):927-35. doi: 10.1002/mus.21780. Epub 2010 Oct 6.

13.

Update on babesiosis.

Vannier E, Krause PJ.

Interdiscip Perspect Infect Dis. 2009;2009:984568. doi: 10.1155/2009/984568. Epub 2009 Aug 27.

14.

Genes up- and down-regulated by dermcidin in breast cancer: a microarray analysis.

Moreira DF, Strauss BE, Vannier E, Belizário JE.

Genet Mol Res. 2008 Sep 30;7(3):925-32.

15.

Human babesiosis.

Vannier E, Gewurz BE, Krause PJ.

Infect Dis Clin North Am. 2008 Sep;22(3):469-88, viii-ix. doi: 10.1016/j.idc.2008.03.010. Review.

16.

Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease.

Ludwiczek O, Vannier E, Moschen A, Salazar-Montes A, Borggraefe I, Gabay C, Enrich B, Kaser A, Siegmund B, Dinarello C, Tilg H.

Scand J Gastroenterol. 2008;43(11):1360-5. doi: 10.1080/00365520802179925.

PMID:
18609176
17.

Persistent and relapsing babesiosis in immunocompromised patients.

Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR 3rd, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A.

Clin Infect Dis. 2008 Feb 1;46(3):370-6. doi: 10.1086/525852.

PMID:
18181735
18.

Shared features in the pathobiology of babesiosis and malaria.

Krause PJ, Daily J, Telford SR, Vannier E, Lantos P, Spielman A.

Trends Parasitol. 2007 Dec;23(12):605-10. Epub 2007 Nov 7. Review.

PMID:
17988944
19.

Resistance training alters cytokine gene expression in skeletal muscle of adults with type 2 diabetes.

Gordon PL, Vannier E, Hamada K, Layne J, Hurley BF, Roubenoff R, Castaneda-Sceppa C.

Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):739-49.

PMID:
17166396
20.

Babesia microti primarily invades mature erythrocytes in mice.

Borggraefe I, Yuan J, Telford SR 3rd, Menon S, Hunter R, Shah S, Spielman A, Gelfand JA, Wortis HH, Vannier E.

Infect Immun. 2006 Jun;74(6):3204-12.

21.

Age-related loss of associations between acute exercise-induced IL-6 and oxidative stress.

Sacheck JM, Cannon JG, Hamada K, Vannier E, Blumberg JB, Roubenoff R.

Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E340-9. Epub 2006 Feb 28.

22.

MyD88-dependent pathways mediate resistance to Cryptosporidium parvum infection in mice.

Rogers KA, Rogers AB, Leav BA, Sanchez A, Vannier E, Uematsu S, Akira S, Golenbock D, Ward HD.

Infect Immun. 2006 Jan;74(1):549-56.

24.

BAEPs averaging analysis using autoregressive modelling.

Vannier E, Naït-Ali A.

J Clin Monit Comput. 2004 Jun;18(3):147-55.

PMID:
15562980
25.

Senescence of human skeletal muscle impairs the local inflammatory cytokine response to acute eccentric exercise.

Hamada K, Vannier E, Sacheck JM, Witsell AL, Roubenoff R.

FASEB J. 2005 Feb;19(2):264-6. Epub 2004 Nov 19.

PMID:
15556970
26.

Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease.

Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA, Tilg H.

Clin Exp Immunol. 2004 Nov;138(2):323-9.

27.

Age-associated decline in resistance to Babesia microti is genetically determined.

Vannier E, Borggraefe I, Telford SR 3rd, Menon S, Brauns T, Spielman A, Gelfand JA, Wortis HH.

J Infect Dis. 2004 May 1;189(9):1721-8. Epub 2004 Apr 19.

PMID:
15116311
28.

Effects of aging and cytokine blockade on inflammatory cachexia.

Fathalla B, Hamada K, Vannier E, Smith D, Edwards C 3rd, Roubenoff R.

Clin Exp Rheumatol. 2004 Jan-Feb;22(1):85-90.

PMID:
15005009
29.
30.

Computer-assisted ABR interpretation using the automatic construction of the latency-intensity curve.

Vannier E, Adam O, Karasinski P, Ohresser M, Motsch JF.

Audiology. 2001 Jul-Aug;40(4):191-201.

PMID:
11521711
31.

IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels.

Buchs N, di Giovine FS, Silvestri T, Vannier E, Duff GW, Miossec P.

Genes Immun. 2001 Jun;2(4):222-8.

32.

IL-4 VNTR gene polymorphism in chronic polyarthritis. The rare allele is associated with protection against destruction.

Buchs N, Silvestri T, di Giovine FS, Chabaud M, Vannier E, Duff GW, Miossec P.

Rheumatology (Oxford). 2000 Oct;39(10):1126-31.

PMID:
11035134
33.

Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.

Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H.

Eur Cytokine Netw. 1999 Mar;10(1):37-42.

35.

Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia.

Barak V, Nisman B, Polliack A, Vannier E, Dinarello CA.

Eur Cytokine Netw. 1998 Mar;9(1):33-9.

36.

Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells.

Takabayashi T, Vannier E, Burke JF, Tompkins RG, Gelfand JA, Clark BD.

J Infect Dis. 1998 Jun;177(6):1622-8.

PMID:
9607842
37.

Menstrual- and gender-dependent variations in circulating IL-1 agonists, antagonists, and binding proteins.

Cannon JG, Abad LW, Vannier E, Lynch EA.

J Leukoc Biol. 1998 Jan;63(1):117-23.

PMID:
9469481
38.

The pattern of interleukin-1beta (IL-1beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections.

van Deuren M, van der Ven-Jongekrijg J, Vannier E, van Dalen R, Pesman G, Bartelink AK, Dinarello CA, van der Meer JW.

Blood. 1997 Aug 1;90(3):1101-8.

PMID:
9242541
39.

Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome.

Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L, Wolff SM, Komaroff AL.

J Clin Immunol. 1997 May;17(3):253-61.

PMID:
9168406
40.

Clinical, hematologic, and immunologic effects of interleukin-10 in humans.

Fuchs AC, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Radwanski E, Affrime MB, Cutler DL, Grint PC, Dinarello CA.

J Clin Immunol. 1996 Sep;16(5):291-303.

PMID:
8886999
41.

Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.

Torcia M, Lucibello M, Vannier E, Fabiani S, Miliani A, Guidi G, Spada O, Dower SK, Sims JE, Shaw AR, Dinarello CA, Garaci E, Cozzolino F.

Exp Hematol. 1996 Jul;24(8):868-74.

PMID:
8690044
43.

A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis.

Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, Gelfand JA.

J Immunol. 1996 May 1;156(9):3455-60.

PMID:
8617973
44.
45.

A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses.

Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA.

J Immunol. 1995 May 15;154(10):5492-9.

PMID:
7730651
46.

Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10.

Chomarat P, Vannier E, Dechanet J, Rissoan MC, Banchereau J, Dinarello CA, Miossec P.

J Immunol. 1995 Feb 1;154(3):1432-9.

PMID:
7822808
48.

Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.

Tilg H, Shapiro L, Vannier E, Poutsiaka DD, Trehu E, Atkins MB, Dinarello CA, Mier JW.

J Immunol. 1994 Mar 15;152(6):3189-98.

PMID:
8144913
49.

Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist.

Schirò R, Longoni D, Rossi V, Maglia O, Doni A, Arsura M, Carrara G, Masera G, Vannier E, Dinarello CA, et al.

Blood. 1994 Jan 15;83(2):460-5.

PMID:
8286744
50.

Cross-linking of the beta-glucan receptor on human monocytes results in interleukin-1 receptor antagonist but not interleukin-1 production.

Poutsiaka DD, Mengozzi M, Vannier E, Sinha B, Dinarello CA.

Blood. 1993 Dec 15;82(12):3695-700.

PMID:
7505123

Supplemental Content

Loading ...
Support Center